Merck’s Bavencio hits targets in bladder cancer interim analysis
Last year the drug disappointed in the Phase III JAVELIN Gastric 100 study, but has pulled itself back with new urothelial carcinoma data.
Read More
Tag: metastatic
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
